Position in FTRE
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$174
+$80 QoQ
Shares Held
10
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GABLES CAPITAL MANAGEMENT INC. holds $190,385 across 9 Biotechnology names. FTRE ranks #6 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRSP |
CRISPR Therapeutics AG
|
2,000 | $109,080 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
121 | $60,104 | |
| 3 | UNCY |
Unicycive Therapeutics, Inc.
|
3,000 | $14,070 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
21 | $5,060 | |
| 5 | IDYA |
IDEAYA Biosciences, Inc.
|
50 | $1,863 | |
| 6 | FTRE |
Fortrea Holdings Inc.
This page
|
10 | $174 | |
| 7 | CVM |
Cel Sci Corp
|
26 | $27 | |
| 8 | LEXX |
Lexaria Bioscience Corp.
|
1 | $7 |
All Filings in FTRE
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $174 | 10 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $94 | 10 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $172 | 10 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $84 | 10 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $49 | 10 | Shares | Sole | 2025-07-30 | |
| 2025-03-31 | $75 | 10 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $186 | 10 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $200 | 10 | Shares | Sole | 2024-10-25 | |
| 2024-06-30 | $233 | 10 | Shares | Sole | 2024-08-08 | |
| 2024-03-31 | $401 | 10 | Shares | Sole | 2024-05-06 | |
| 2023-12-31 | $349 | 10 | Shares | Sole | 2024-02-08 | |
| 2023-09-30 | $285 | 10 | Shares | Sole | 2023-11-03 | |
| No filing history on record for this holder in this stock. | ||||||